Injecto A/S

Injecto A/S develops, manufactures, and sells components for pharmaceutical packaging mainly for pre-fillable injection systems (“PFS”) on the basis of the licenses on patent rights from Injecto Group A/S.Injecto A/S’ main focus is the series of lubrigone plunger stoppers for PFS in ISO measurements, but also in individual measurements based on specific customer specifications. The lubrigone plunger stoppers ensure a lubrication free PFS, which is in demand from pharma companies specialised in biologics and in medical preparations for sensitive organs like eyes, ears, central nervous system, brain etc.The company has established two fully validated production lines at SP Medical (www.sp-medical.com) as its OEM manufacturer on lubrigone3 plunger stoppers for PFS in respectively a volume of 0.5 ml and 1.0 ml (long) and has increased its contacts with the world’s leading pharma companies and some of the leading manufacturers in PFS. Especially the concern of PFAS among pharma companies and the lubrigone stoppers’ capability to be used in connection with deep cold storage temperatures of minus 80 degress celcius seem to be two driving forces, where PFAS based on the latest developments seems to be an even more important and maybe determining factor.The awareness of PFAS will open new market opportunities and it is much more likely that there will be a substantial market over the coming years for conversions where pharma products supplied in vials will be replaced by the same products in PFS.Injecto A/S’ third production line for lubrigone stoppers for 1-3 ml (2,25 ml) PFS in ISO measurements in addition to the two aforementioned production lines has been slightly delayed, but we expect to have a validated production line in place within 6 months from now. However, we expect to be able to deliver test samples for the pharma companies from this third production line shortly.The additional production line will ensure that Injecto A/S’ can supply samples in all three basic ISO measurements of PFS for tests from an industrial production to pharma customers and at the same time offer those pharma customers industrial supplies without bottlenecks.Due to Injecto A/S’ strong competitive edge related to the flexibility and efficient production based on the lubrigone concept Injecto A/S can offer the pharma companies and companies in other business areas such as diagnostics a strong value proposition with respect to the development of the best individual solution and with a much shorter timeline related to a production in industrial scale. Furthermore, we get enquiries re. larger volumes.Injecto A/S’ products are supplied as primary packaging for pharma, which supplies are defined by extensive testing and hence longer lead times. The longer lead times are matched by long-term, lucrative contracts. However, supplies for conversions will shorten the time to market.In order to increase Injecto’s position in the market we have enhanced our Quality Management System and obtained an ISO 9001 and ISO 15378 certification for our plunger stopper production.By the three industrial production lines Injecto A/S has verified production times and production costs and has built up a production capacity that over the coming years will ensure a substantial revenue and a significant profit without further investments. Injecto A/S has also verified that a further scale-up of Injecto Group A/S’ current yearly production capacity of a two-digit million figure within 9-12 months can be increased to a yearly production capacity in a three-digit million figure.In March 2025 we signed a Strategic Framework Supply Agreement with the global leading provider, Gerresheimer (www.gerresheimer.com). The signing of the contract was made public by the parties in April 2025 and has attracted much attention and contributed to initiating supplementary projects with pharma customers.The sales forecasts in the contract for the coming 5 years shows that Injecto is not just on its way into commercial operation, but also with an expected successful EBITDA within reasonable time.Injecto A/S has supported its parent company’s co-operation with PATH (www.path.org) and PATH’s donators and some pharma companies related to the easyject syringe, but dependable on the outcome and the resources Injecto A/S and its parent company will consider if the production and sales and marketing of the easyject syringe shall be carried out by another subsidiary under Injecto Group A/S.